Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--True North Therapeutics, a clinical stage biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback